> Detailanzeige

Stahler, Arndt; Stintzing, Sebastian; Modest, Dominik Paul; Ricard, Ingrid; Kapaun, Christine; Ivanova, Boryana; Vehling-Kaiser, Ursula; Fischer von Weikersthal, Ludwig; Schalhorn, Andreas; Stauch, Martina; Kiani, Alexander; Neumann, Jens; Kirchner, Thomas; Heinemann, Volker

High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3
  • Beteiligte: Stahler, Arndt; Stintzing, Sebastian; Modest, Dominik Paul; Ricard, Ingrid; Kapaun, Christine; Ivanova, Boryana; Vehling-Kaiser, Ursula; Fischer von Weikersthal, Ludwig; Schalhorn, Andreas; Stauch, Martina; Kiani, Alexander; Neumann, Jens; Kirchner, Thomas; Heinemann, Volker
  • Erschienen: American Society of Clinical Oncology (ASCO), 2020
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2020.38.15_suppl.4026
  • ISSN: 1527-7755; 0732-183X
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> 4026 </jats:p><jats:p> Background: Amphiregulin ( AREG) and epiregulin ( EREG) were discussed as biomarkers for treatment of metastatic colorectal cancer (mCRC). Data from randomized controlled trials (RCT) are limited. Methods: AREG and EREG mRNA expression by RTqPCR in relation to housekeeping genes were available from 688 patients of three RCT (FIRE-1, n = 192, FUFIRI vs. mIrOx; CIOX, n = 113, cetuximab + CAPIRI/CAPOX; FIRE-3, n = 383, FOLFIRI+cetuximab/bevacizumab) and were normalized to their respective range of each trial with median and 3rd quartile as threshold values. Kaplan-Meier estimated overall survival (OS) and progression-free survival (PFS). Cox regression analysis calculated hazard ratio (HR) and 95% confidence interval (95% CI). Overall response rate (ORR) was compared by chi square test. Results: Across all trials, high AREG mRNA expression appeared as strong prognostic biomarker for OS, PFS and ORR for all threshold values. In RAS wildtype patients, high AREG expression was associated with better OS and PFS for cetuximab but not bevacizumab treatment. (Table) No effects were seen for epiregulin when all trials were analysed together. Conclusions: High AREG mRNA expression appeared as strong prognostic biomarker in mCRC. Positive predictive information might exist for cetuximab treatment. [Table: see text] </jats:p>
  • Zugangsstatus: Freier Zugang